Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 3

2(33.3%)

6Total

Phase 1(4)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07308041Phase 1Completed

A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of Amoxicillin

Role: lead

NCT07313774Phase 3Not Yet Recruiting

A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)

Role: lead

NCT07037875Phase 3Not Yet Recruiting

A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)

Role: lead

NCT05742984Phase 1Completed

Investigate Linaprazan Glurate/Linaprazan in Healthy Subjects

Role: lead

NCT05627518Phase 1Completed

Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation

Role: lead

NCT05633147Phase 1Completed

Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam

Role: lead

All 6 trials loaded